51ºÚÁϳԹÏÍø

Journal of Pulmonology and Respiratory Diseases
51ºÚÁϳԹÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 51ºÚÁϳԹÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

51ºÚÁϳԹÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Mini Review   
  • J Pulm Res Dis 2024,

Review of Infliximab Therapy in Chronic Inflammatory Diseases: Mechanisms and Clinical Outcomes

Khanduja Di*
Cruces University Hospital-Biocruces Health Research Institute, Barakaldo, Spain
*Corresponding Author : Khanduja Di, Cruces University Hospital-Biocruces Health Research Institute, Barakaldo, Spain, Email: dkhanduj84@gmail.com

Received Date: Apr 01, 2024 / Published Date: Apr 30, 2024

Abstract

Infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), has revolutionized the treatment landscape of chronic inflammatory diseases. This review comprehensively explores the mechanisms of action, therapeutic indications, and clinical outcomes associated with Infliximab therapy across various conditions.

Citation: Khanduja D (2024) Review of Infliximab Therapy in Chronic InflammatoryDiseases: Mechanisms and Clinical Outcomes. J Pulm Res Dis 8: 194.

Copyright: © 2024 Khanduja D. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top